There is an immense urgency for the development of new cancer therapies owing to the 1.5 million individuals diagnosed with cancer each year. Over 85% of human cancers are solid tumours and the prognosis for patients with advanced solid tumours is extremely poor. Modern anticancer drug discovery targets molecular aberrations that are specific to tumour cells. Carbonic anhydrases (CAs) are a recently validated cancer drug target that is tumour specific. the aim of this research is to evaluate the inhibition of CAs with small molecules as a new approach for treatment of solid tumours. Our research will underpin development of safe and effective first-in-class drug treatment options for the benefit of cancer patients and clinicians worldwide.
|Effective start/end date||1/01/11 → 31/12/13|
- Australian Research Council (ARC): A$45,000.00